Browse the evidence

Non-pharmacological lifestyle interventions (caloric deficit >500 kcal/day, physical activity >200 min/week) can achieve up to 8% mean weight loss over 6 months, comparable to moderate-efficacy anti-obesity medications.

Start with a 500 kcal daily deficit and aim for over 200 minutes of physical activity per week. This can yield up to 8% weight loss in 6 months, matching moderate drugs, but requires long-term adherence to prevent regain.

Endoscopic Sleeve Gastroplasty (ESG) achieves 16-20% total weight loss at 12 months and improves metabolic markers without worsening GERD.

ESG is a minimally invasive procedure that reduces stomach size by 70-80% using sutures. It achieves 16-20% weight loss at one year and improves blood pressure and diabetes markers. Unlike some surgeries, it does not typically worsen acid reflux. It is suitable for those with a BMI of 30-50 who want a less invasive option than traditional surgery.

Significant weight loss (≥15% body weight) achieved through intensive dietary intervention can induce remission of type 2 diabetes in a majority of patients.

To potentially reverse Type 2 Diabetes, you must lose a significant amount of weight—specifically 15% or more of your body weight. This usually requires a structured, intensive dietary intervention (like total diet replacement) under medical supervision, not just 'eating less'. The goal is to remove fat from your liver and pancreas to restore their normal function.

Tirzepatide (5, 10, and 15 mg) is a cost-effective treatment for weight management compared to liraglutide in the UK, demonstrating dominance (cost savings and QALY gains) in the general obesity trial population and favorable ICERs in the specific NICE-reimbursed population.

For patients in the UK with obesity or overweight plus complications, tirzepatide (5, 10, or 15 mg weekly) combined with diet and exercise is a cost-effective treatment option compared to liraglutide. It offers potential cost savings and quality-of-life gains, and unlike liraglutide which is restricted to specialist services, tirzepatide can be prescribed in primary care.

Tirzepatide reduces the incidence of obesity-related complications, specifically knee replacements (29-46% reduction) and type 2 diabetes (25-48% reduction), compared to liraglutide.

Tirzepatide treatment is associated with significantly lower rates of knee replacements and type 2 diabetes compared to liraglutide, likely due to greater weight loss and prediabetes reversal.

Dual incretin agonists (e.g., tirzepatide) and newer GLP-1 receptor agonists (e.g., semaglutide) provide superior glycaemic control and greater weight reduction compared to earlier GLP-1 agents.

If you have Type 2 Diabetes, newer injectable medications like tirzepatide or semaglutide are significantly more effective at lowering blood sugar and reducing weight than older GLP-1 drugs. Discuss these options with your doctor, especially if you are struggling with weight or glucose control despite previous treatments.

Continuous Glucose Monitoring (CGM) significantly improves glycaemic outcomes in Type 2 Diabetes patients compared to standard self-monitoring.

Using a Continuous Glucose Monitor (CGM) can help you manage Type 2 Diabetes more effectively than traditional finger-prick tests. Studies show it can lower your average blood sugar (HbA1c) by 0.5-1.0%. While cost and insurance coverage can be hurdles, the real-time feedback helps you make better daily choices.

Long-acting GLP-1 receptor agonists (semaglutide and dulaglutide) provide superior efficacy, particularly in cardio-renal protection, and overall value compared to other long-acting GLP-1RAs in China, earning strong clinical recommendations.

For patients with Type 2 Diabetes in China, Semaglutide and Dulaglutide are the preferred long-acting GLP-1 receptor agonists. They offer strong recommendations due to superior efficacy, particularly in protecting the heart and kidneys, and better overall value. While newer drugs like Tirzepatide show great potential for weight loss and glucose control, their high cost and lack of insurance coverage make them less accessible. Patients should discuss these options with their doctors, prioritizing agents with established cardiovascular benefits and insurance coverage.

Treatment with tirzepatide (10-15 mg weekly) causes significant shifts to lower BMI categories in adults with obesity, which is associated with substantial improvements in cardiometabolic risk factors including blood pressure, fasting insulin, and lipid profiles.

If you have obesity or overweight with related health issues like high blood pressure or high cholesterol, talk to your doctor about tirzepatide. It is a once-weekly injection that helps many people move to a lower BMI category, which is linked to better heart health and metabolic markers. It works best when combined with a reduced-calorie diet and increased physical activity.

Tirzepatide, a dual GLP-1 and GIP receptor agonist, produces significant weight loss (exceeding 20% body weight in some cases) and improves glycemic control in patients with type 2 diabetes and obesity.

Tirzepatide is a weekly injection that mimics gut hormones to significantly reduce weight (often >20%) and improve blood sugar. It works best when paired with diet and exercise. Start with lower doses to minimize stomach issues like nausea, which usually improve over time.

Tirzepatide, a dual GIP/GLP-1 receptor agonist administered once weekly, produces significant weight loss (8.6% to 20.9%) and metabolic improvements in obese patients, outperforming placebo and demonstrating superior efficacy compared to semaglutide in head-to-head comparisons.

Tirzepatide is a once-weekly injection that helps obese patients lose significant weight (up to 20%) and improves blood sugar and heart risk factors. It works by mimicking hormones that regulate appetite and digestion. While it can cause temporary stomach issues like nausea, it is generally well-tolerated and more effective than some other existing weight-loss drugs. Medical supervision is required to manage dosing and side effects.

Resistance training is essential during weight loss to prevent muscle loss and maintain basal metabolic rate, thereby preventing weight regain.

Include strength training 2-4 times a week. Use weights or machines that allow you to do 10-15 reps with moderate effort (60-70% of your max). Focus on large muscle groups (legs, back, chest). This protects your muscle while you diet.

Behavioral therapy is a mandatory component of obesity treatment, requiring at least 6 months of intervention for weight loss and 1 year for maintenance to ensure adherence.

Track your food, weight, and activity daily. Set realistic goals. Attend counseling sessions weekly for the first 6 months. If you don't lose at least 2.5% of your body weight in the first month, ask for more intensive support.

High-protein diets (>2.0 g/kg/day) are safe for healthy, highly qualified athletes, showing no adverse changes in blood biochemistry or bone mineral density.

If you are a healthy athlete, eating more than 2 grams of protein per kilogram of body weight is safe and will not harm your kidneys or bones.

During caloric restriction, higher protein intake (2.3–3.1 g/kg of fat-free mass) helps preserve lean body mass and reduces fat mass.

If you are cutting calories to lose fat, increase your protein to 2.3–3.1 grams per kilogram of your fat-free mass (or total body weight if you don't know your FFM) to protect your muscle.

Resistance-trained young adults consume significantly higher absolute and relative protein intakes (averaging 1.6–2.0 g/kg/day) than recreationally active peers, with animal-derived proteins comprising the majority (approx. 68-72%) of total intake.

If you lift weights regularly, you are likely eating more protein than the average person, averaging 1.6 to 2.0 grams per kilogram of body weight. Most of this comes from animal sources. This is normal and expected for your activity level. You do not need to worry about the RDA of 0.8 g/kg, as your intake is already well above that threshold.

Micellar casein (MC) consumed at sahur partially mitigates fasting-induced declines in anaerobic power (Wingate peak and mean power) and upper-body strength (bench press) in combat sport athletes during Ramadan, outperforming whey protein isolate and placebo.

If you are fasting for 11+ hours (like during Ramadan) and competing in anaerobic sports, take 0.4g/kg of Micellar Casein with your pre-dawn meal. This slow-digesting protein helps maintain your power output better than Whey Protein or no protein, though it won't fully restore you to fed-state levels.

Vegetarian athletes must pay special attention to micronutrients (Iron, Zinc, Calcium, Vitamin D, Vitamin B12) to support muscle development and prevent deficiencies that could impair performance.

Monitor your levels of Iron, Zinc, Calcium, Vitamin D, and B12. Plant-based diets can be lower in these nutrients, so consider fortified foods or supplements to ensure optimal muscle function and recovery.

Prioritizing protein intake maximizes the Thermic Effect of Food (TEF), thereby increasing total energy expenditure compared to high-fat or high-carbohydrate diets at equal caloric levels.

To burn more calories through digestion, prioritize protein in your meals. Protein has a much higher thermic effect (20-30%) compared to fat (2-5%) and carbs (5-15%). This means you burn more energy just processing protein-rich foods.

A weight gain of ≥5% over a 3-year period significantly increases the risk of incident type 2 diabetes, while a weight loss of ≥5% significantly decreases it, independent of attained weight.

To lower your risk of type 2 diabetes, aim for a weight change of at least 5% of your body weight over a few years. Losing 5% or more significantly reduces your risk, while gaining 5% or more significantly increases it. This benefit exists regardless of your final weight, meaning the act of changing your weight matters for your metabolic health.

Aggressive weight loss management is the primary first step for treating type 2 diabetes, as diet can effectively lead to remission through progressively greater degrees of weight loss improving insulin sensitivity.

If you have recently been diagnosed with type 2 diabetes, focus on losing weight through diet as your first priority. The more weight you lose, the better your insulin sensitivity becomes, and this can lead to remission of the disease.

Weight loss achieved through caloric restriction, exercise, or bariatric surgery reduces the Apnea-Hypopnea Index (AHI) in patients with Obstructive Sleep Apnea (OSA) and Obesity Hypoventilation Syndrome (OHS), with the magnitude of AHI reduction correlating non-linearly with the percentage of BMI reduction.

Losing weight is one of the most effective ways to reduce the severity of sleep apnea. You do not need to reach a 'perfect' weight to see benefits; even a 10% reduction in body weight can significantly lower the number of breathing interruptions during sleep. If lifestyle changes (diet and exercise) do not show improvement in your sleep metrics within 3 months, consult your doctor about escalating to pharmacotherapy (like GLP-1 agonists) or bariatric surgery, which can induce remission in many cases.

Combining energy restriction with resistance or mixed exercise training is more effective for reducing body fat and preserving/increasing muscle mass than energy restriction alone.

To lose fat without losing muscle, combine a moderate calorie deficit with resistance training (2-3 times per week) and/or mixed exercise. Ensure you are eating enough protein (1.1-1.7 g/kg body weight). This combination yields the best body composition changes, superior to diet or exercise alone.

Physical activity, particularly resistance and mixed exercise, reduces visceral adipose tissue more effectively than caloric restriction alone.

If your goal is to reduce dangerous visceral fat, prioritize exercise over strict dieting. Exercise has a stronger effect on reducing visceral fat than caloric restriction alone. Combine this with a healthy diet for best overall results.